483 Xellia Pharmaceuticals USA Feb 2022

483 Xellia Pharmaceuticals USA Feb 2022

Andrew Barrowcliff FDA, Lisa Hilliard FDA$119.00 - Available Now

FDA investigators audited the Xellia Pharmaceuticals USA - Bedford, OH, United States facility and issued inspectional observations (via FDA 483) on 07 Feb 2022.

Product details

  • Category: Human Drugs
  • Inspection end: 07 Feb 2022
  • Location: Bedford, United States
  • FEI: 3012279857
Add To Cart